Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...

December 2024 was declared a "high severity" flu season by the Centre for Disease Control (CDC), the worst in over half a decade. Hospitalization rates were up to 2.8 times higher than the median ...

A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...

A new perspective paper explores the current state and future directions of precision medicine in colorectal cancer (CRC). It outlines advancements in molecular testing and their implications for ...

CT screening for lung cancer could save countless lives, but low participation rates have led to some eyebrow-raising proposals. Molecular methods, touted by those with a vested interest, promise to ...

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...

SkylineDx said it published new peer-reviewed data where its Merlin CP-GEP Test outperforms the competition and current standards of care for identifying melanoma risk using molecular testing. In ...

IVDR: where are we now in molecular testing? How IVDR implementation is progressing in molecular biology laboratories in different European countries IVDR, the new EU legislation for in-vitro ...

3EO becomes the first point-of-care molecular technology to be retail priced below $15 per test. 3EO adds a breakthrough business model enabling more physician practices to upgrade technology from ...

Gastrointestinal (GI) infections present a formidable challenge to healthcare systems. As we navigate this landscape, we recognize that there are numerous benefits when moving from conventional to ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first ...